A recent study published in Genes & Development reveals that the MYC oncoprotein, long known to drive tumor proliferation and metabolism, also plays a direct role in DNA repair. In work led by researchers at Oregon Health & Science University, a modified form of MYC was shown to localize to sites of chemotherapy- or replication-induced DNA damage, recruiting repair proteins and enabling cancer cells to survive genotoxic stress. This non-canonical function was particularly evident in patient-derived pancreatic cancer models, where elevated MYC activity correlated with enhanced DNA-repair capacity, treatment resistance, and poorer clinical outcomes. The findings help explain why MYC-driven malignancies, including many aggressive solid tumors encountered in Indian oncology practice, frequently recur after platinum- or radiation-based regimens.
These observations carry immediate translational relevance. Pharmacologic strategies that selectively disrupt MYC-mediated repair without abolishing its physiologic transcriptional roles could sensitize tumors to existing DNA-damaging therapies. Early-phase “window-of-opportunity” trials evaluating first-in-class MYC inhibitors are already under way; Indian oncologists managing pancreatic, lung, and triple-negative breast cancers may soon need to incorporate MYC-status assessment into treatment algorithms. Such approaches could improve response rates in a population where late-stage presentation remains common.
